DITPA has been investigated in Congestive Heart Failure.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ritanserin | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Ritanserin. |
| Alaproclate | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Alaproclate. |
| Citalopram | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Citalopram. |
| Fluoxetine | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Fluoxetine. |
| Duloxetine | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Duloxetine. |
| Trazodone | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Trazodone. |
| Paroxetine | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Paroxetine. |
| Sertraline | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Sertraline. |
| Sibutramine | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Sibutramine. |
| Escitalopram | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Escitalopram. |
| Dapoxetine | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Dapoxetine. |
| Pitolisant | The serum concentration of 3,5-diiodothyropropionic acid can be decreased when it is combined with Pitolisant. |
| Metreleptin | The metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Metreleptin. |
| Amphetamine | The risk or severity of adverse effects can be increased when Amphetamine is combined with 3,5-diiodothyropropionic acid. |
| Phentermine | The risk or severity of adverse effects can be increased when Phentermine is combined with 3,5-diiodothyropropionic acid. |
| Midodrine | The risk or severity of adverse effects can be increased when Midodrine is combined with 3,5-diiodothyropropionic acid. |
| Norepinephrine | The risk or severity of adverse effects can be increased when Norepinephrine is combined with 3,5-diiodothyropropionic acid. |
| Phenylephrine | The risk or severity of adverse effects can be increased when Phenylephrine is combined with 3,5-diiodothyropropionic acid. |
| Phenylpropanolamine | The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with 3,5-diiodothyropropionic acid. |
| Metaraminol | The risk or severity of adverse effects can be increased when Metaraminol is combined with 3,5-diiodothyropropionic acid. |
| Epinephrine | The risk or severity of adverse effects can be increased when Epinephrine is combined with 3,5-diiodothyropropionic acid. |
| Methoxamine | The risk or severity of adverse effects can be increased when Methoxamine is combined with 3,5-diiodothyropropionic acid. |
| Orciprenaline | The risk or severity of adverse effects can be increased when Orciprenaline is combined with 3,5-diiodothyropropionic acid. |
| Phenmetrazine | The risk or severity of adverse effects can be increased when Phenmetrazine is combined with 3,5-diiodothyropropionic acid. |
| Dobutamine | The risk or severity of adverse effects can be increased when Dobutamine is combined with 3,5-diiodothyropropionic acid. |
| Pseudoephedrine | The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 3,5-diiodothyropropionic acid. |
| Benzphetamine | The risk or severity of adverse effects can be increased when Benzphetamine is combined with 3,5-diiodothyropropionic acid. |
| Ritodrine | The risk or severity of adverse effects can be increased when Ritodrine is combined with 3,5-diiodothyropropionic acid. |
| Terbutaline | The risk or severity of adverse effects can be increased when Terbutaline is combined with 3,5-diiodothyropropionic acid. |
| Oxymetazoline | The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 3,5-diiodothyropropionic acid. |
| Diethylpropion | The risk or severity of adverse effects can be increased when Diethylpropion is combined with 3,5-diiodothyropropionic acid. |
| Dopamine | The risk or severity of adverse effects can be increased when Dopamine is combined with 3,5-diiodothyropropionic acid. |
| Isoprenaline | The risk or severity of adverse effects can be increased when Isoprenaline is combined with 3,5-diiodothyropropionic acid. |
| Lisdexamfetamine | The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with 3,5-diiodothyropropionic acid. |
| Fenoterol | The risk or severity of adverse effects can be increased when Fenoterol is combined with 3,5-diiodothyropropionic acid. |
| Ephedrine | The risk or severity of adverse effects can be increased when Ephedrine is combined with 3,5-diiodothyropropionic acid. |
| Mephentermine | The risk or severity of adverse effects can be increased when Mephentermine is combined with 3,5-diiodothyropropionic acid. |
| Procaterol | The risk or severity of adverse effects can be increased when Procaterol is combined with 3,5-diiodothyropropionic acid. |
| Clenbuterol | The risk or severity of adverse effects can be increased when Clenbuterol is combined with 3,5-diiodothyropropionic acid. |
| MMDA | The risk or severity of adverse effects can be increased when MMDA is combined with 3,5-diiodothyropropionic acid. |
| Midomafetamine | The risk or severity of adverse effects can be increased when Midomafetamine is combined with 3,5-diiodothyropropionic acid. |
| 2,5-Dimethoxy-4-ethylamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with 3,5-diiodothyropropionic acid. |
| 4-Bromo-2,5-dimethoxyamphetamine | The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with 3,5-diiodothyropropionic acid. |
| Tenamfetamine | The risk or severity of adverse effects can be increased when Tenamfetamine is combined with 3,5-diiodothyropropionic acid. |
| Chlorphentermine | The risk or severity of adverse effects can be increased when Chlorphentermine is combined with 3,5-diiodothyropropionic acid. |
| Methylenedioxyethamphetamine | The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with 3,5-diiodothyropropionic acid. |
| Dextroamphetamine | The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with 3,5-diiodothyropropionic acid. |
| Metamfetamine | The risk or severity of adverse effects can be increased when Metamfetamine is combined with 3,5-diiodothyropropionic acid. |
| Nylidrin | The risk or severity of adverse effects can be increased when Nylidrin is combined with 3,5-diiodothyropropionic acid. |
| Tetryzoline | The risk or severity of adverse effects can be increased when Tetryzoline is combined with 3,5-diiodothyropropionic acid. |
| Tyramine | The risk or severity of adverse effects can be increased when Tyramine is combined with 3,5-diiodothyropropionic acid. |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Isoxsuprine is combined with 3,5-diiodothyropropionic acid. |
| Etilefrine | The risk or severity of adverse effects can be increased when Etilefrine is combined with 3,5-diiodothyropropionic acid. |
| Synephrine | The risk or severity of adverse effects can be increased when Synephrine is combined with 3,5-diiodothyropropionic acid. |
| Iofetamine I-123 | The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with 3,5-diiodothyropropionic acid. |
| Racepinephrine | The risk or severity of adverse effects can be increased when Racepinephrine is combined with 3,5-diiodothyropropionic acid. |
| Ritobegron | The risk or severity of adverse effects can be increased when Ritobegron is combined with 3,5-diiodothyropropionic acid. |
| Tramazoline | The risk or severity of adverse effects can be increased when Tramazoline is combined with 3,5-diiodothyropropionic acid. |
| Mephedrone | The risk or severity of adverse effects can be increased when Mephedrone is combined with 3,5-diiodothyropropionic acid. |
| Fenozolone | The risk or severity of adverse effects can be increased when Fenozolone is combined with 3,5-diiodothyropropionic acid. |
| Methoxyphenamine | The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with 3,5-diiodothyropropionic acid. |
| Tretoquinol | The risk or severity of adverse effects can be increased when Tretoquinol is combined with 3,5-diiodothyropropionic acid. |
| Gepefrine | The risk or severity of adverse effects can be increased when Gepefrine is combined with 3,5-diiodothyropropionic acid. |
| Prenalterol | The risk or severity of adverse effects can be increased when Prenalterol is combined with 3,5-diiodothyropropionic acid. |
| Mefenorex | The risk or severity of adverse effects can be increased when Mefenorex is combined with 3,5-diiodothyropropionic acid. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with 3,5-diiodothyropropionic acid. |
| Labetalol | The risk or severity of adverse effects can be increased when Labetalol is combined with 3,5-diiodothyropropionic acid. |
| Acebutolol | The risk or severity of adverse effects can be increased when Acebutolol is combined with 3,5-diiodothyropropionic acid. |
| Celiprolol | The risk or severity of adverse effects can be increased when Celiprolol is combined with 3,5-diiodothyropropionic acid. |
| Bucindolol | The risk or severity of adverse effects can be increased when Bucindolol is combined with 3,5-diiodothyropropionic acid. |
| Epanolol | The risk or severity of adverse effects can be increased when Epanolol is combined with 3,5-diiodothyropropionic acid. |
| Gefitinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Gefitinib. |
| Sorafenib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Sorafenib. |
| Erlotinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Erlotinib. |
| Imatinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Imatinib. |
| Lapatinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Lapatinib. |
| Sunitinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Sunitinib. |
| Genistein | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Genistein. |
| 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone. |
| Geldanamycin | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Geldanamycin. |
| PD173955 | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with PD173955. |
| Radicicol | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Radicicol. |
| Cediranib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Cediranib. |
| Vatalanib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Vatalanib. |
| Vandetanib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Vandetanib. |
| Canertinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Canertinib. |
| Tandutinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Tandutinib. |
| Motesanib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Motesanib. |
| Dovitinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Dovitinib. |
| Glesatinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Glesatinib. |
| Lestaurtinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Lestaurtinib. |
| Pazopanib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Pazopanib. |
| Bosutinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Bosutinib. |
| Axitinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Axitinib. |
| Piceatannol | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Piceatannol. |
| Crizotinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Crizotinib. |
| Cabozantinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Cabozantinib. |
| Ruxolitinib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Ruxolitinib. |
| Vemurafenib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Vemurafenib. |
| Regorafenib | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Regorafenib. |